Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05522361 · ClinicalTrials.gov registry record · Phase 4
Risdiplam in Patients With Spinal Muscular Atrophy Previously Treated With Nusinersen
A Phase 4 study of Spinal Muscular Atrophy, sponsored by Clinic for Special Children.
- Active
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05522361: Active Phase 4 study of Spinal Muscular Atrophy, sponsored by Clinic for Special Children.
NCT05522361 is a Phase 4 study of Spinal Muscular Atrophy that is active but no longer recruiting, run by Clinic for Special Children. The registered enrollment target is 10 participants, below the 109-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05522361, a Phase 4 study of Spinal Muscular Atrophy, is active but no longer recruiting, sponsored by Clinic for Special Children.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Risdiplam Exchange (RISE) is a study of spinal muscular atrophy (SMA) patients who crossover to 36 months of open-label risdiplam monotherapy following a comparable period of nusinersen treatment. The schedule of assessments (SOAs) carry over seamlessly for the cohort from studies done while treated with nusinersen and continue to track the most informative outcomes from that trial (e.g. nine hole peg test and grip strength), while adding the Box and Block Test (BBT) as an additional measure of upper limb endurance and function.
Conditions Studied
Interventions
- DRUG Risdiplam
Study Locations (1)
Pennsylvania
- Clinic for Special Children - Strasburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-11-06 |
| Est. Completion | 2026-06-15 |
| Phase | Phase 4 |
What the registry record for NCT05522361 still lists
NCT05522361 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 109-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Spinal Muscular Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Risdiplam is the first listed.
NCT05522361 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05522361 about?
NCT05522361 is a clinical study titled "Risdiplam in Patients With Spinal Muscular Atrophy Previously Treated With Nusinersen". Risdiplam Exchange (RISE) is a study of spinal muscular atrophy (SMA) patients who crossover to 36 months of open-label risdiplam monotherapy following a comparable period of nusinersen treatment. The schedule of assessments (SOAs) carry over seamlessly for the cohort from studies done while treated...
What is the current status of trial NCT05522361?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2022-11-06. Estimated completion is 2026-06-15.
What conditions does trial NCT05522361 study?
This clinical trial studies the following conditions: Spinal Muscular Atrophy.
What interventions are being tested in trial NCT05522361?
The interventions under investigation include: Risdiplam (DRUG).
Who is sponsoring clinical trial NCT05522361?
This trial is sponsored by Clinic for Special Children, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05522361 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Muscular Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05522361's enrollment target sits among peer trials
10 20th of 22 higher than 3 of 22 other Spinal Muscular Atrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Spinal Muscular Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
ACTIVE NOT RECRUITING · Phase 4
-
Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA
RECRUITING
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
RECRUITING · Phase 2
-
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
RECRUITING · NA
-
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI